54 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) climbed 79.3% to $14.93 after the company announced positive interim results from the Phase 1 trial with FTX-6058 in healthy adult volunteers.
Credit Suisse Maintains Underperform on Fulgent Genetics, Raises Price Target to $65
Credit Suisse analyst Katie Tryhane maintains Fulgent Genetics (NASDAQ:FLGT) with a Underperform and raises the price target from $55 to $65.
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 9)
Fulgent Genetics Stock Falls As Q2 Earnings Miss Street Estimates; Lowers FY21 Sales Outlook
Fulgent Genetics Inc (NASDAQ:FLGT) reported after the close of the market on Monday that its second-quarter revenues increased nearly ninefold,…
Recap: Fulgent Genetics Q2 Earnings
Shares of Fulgent Genetics (NASDAQ:FLGT) decreased in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 1400.00% year over year to $2.55, which missed the estimate of $2.81.
Fulgent Genetics Q2 EPS $2.55 Misses $2.81 Estimate, Sales $153.62M Miss $197.34M Estimate
Fulgent Genetics (NASDAQ:FLGT) reported quarterly earnings of $2.55 per share which missed the analyst consensus estimate of $2.81 by 9.25 percent. This is a 1400 percent increase over earnings of $0.17 per share from
Fulgent Genetics And Helio Health Announce Partnership To Commercialize Early Cancer Detection Tests; Financial Details Not Disclosed
Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and
Fulgent Genetics Reports Purchase Of CSI Labs, No Terms Disclosed
Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent” or the “Company”), a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and